Can we predict the course of a rare liver disease?
NCT ID NCT07744048
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This study looks at a rare liver condition called porto-sinusoidal vascular disease (PSVD), which is diagnosed with a liver biopsy. The researchers are collecting detailed medical information from 150 patients to track their health over time, including survival and liver-related complications. The goal is to identify factors that influence how the disease progresses and to find which patients may be at higher risk, ultimately helping doctors make better management decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could improve understanding of PSVD, helping doctors identify high-risk patients and manage the disease more precisely.
- What could go wrong
- This is an observational study, so it cannot prove what causes PSVD or test new treatments. The findings may not apply to all patients, and the study's size and design may limit the strength of its conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study includes adult patients aged 18 years and older with histopathologically confirmed porto-sinusoidal vascular disease (PSVD) via liver biopsy and no histological evidence of cirrhosis. All subjects are inpatients and outpatients from Beijing Ditan Hospital, covering subgroups with or without portal vein thrombosis, portal hypertension, known etiologies or concurrent chronic liver diseases. Patients with Budd-Chiari syndrome, hepatic venous outflow obstruction, congenital hepatic fibrosis, sinusoidal obstruction syndrome, hepatic malignancies or severely incomplete clinical data are excluded.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients histopathologically diagnosed with porto-sinusoidal vascular disorder (PSVD) via liver needle biopsy; 2. Liver biopsy specimen length ≥ 10 mm (or assessed as diagnostically adequate by a pathologist), with no histological evidence of cirrhosis; 3. Meeting the established diagnostic criteria for PSVD. Exclusion Criteria: 1. Concomitant Budd-Chiari syndrome or other hepatic venous outflow obstruction diseases; 2. Concomitant congenital hepatic fibrosis, hepatic sarcoidosis, or sinusoidal obstruction syndrome; 3. Concomitant hepatocellular carcinoma or other hepatic malignancies; 4. Age \< 18 years; 5. Severe deficiency of clinical data that precludes valid analysis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Porto-sinusoidal vascular diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100015, China